+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Efficacy of an inactivated canine coronavirus vaccine in pups



Efficacy of an inactivated canine coronavirus vaccine in pups



New Microbiologica 26(2): 151-155



The efficacy of an inactivated CCoV vaccine (Duramune PC) was evaluated in four pups. Two dogs were maintained non-vaccinated. Ten days after the booster shot all the pups were challenged with a field CCoV strain administered by oro-nasal route. The vaccinated pups did not display clinical signs and shed the challenge-virus for 11.25 days, evaluated by virus isolation, and 13.5 days, evaluated by PCR assay. The two non vaccinated pups displayed mild diarrhoea at day post-challenge 4 and shed the challenge-virus for 14 and 15 days respectively, by virus isolation, and for 22 and 24 days respectively, by PCR assay.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 004139828

Download citation: RISBibTeXText

PMID: 12737196


Related references

Efficacy of an inactivated vaccine against clinical disease caused by canine coronavirus. Advances in Experimental Medicine and Biology 380: 229-234, 1995

Inactivated canine coronavirus vaccine us patent 4567042. jan. 28 1986. Official Gazette of the United States Patent & Trademark Office Patents 1062(4): 1588, 1986

Efficacy of a new canine origin, modified live virus vaccine against canine coronavirus. Canine Practice 24(1): 6-9, 1999

Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys. Vaccine 23(24): 3202-3209, 2005

Efficacy of an inactivated canine adenovirus-type 2 vaccine. VM SAC veterinary medicine and small animal clinician 78(1): 51-59, 1983

Safety and efficacy of a modified-live canine coronavirus vaccine in dogs. Veterinary Microbiology 99(1): 43-49, 2004

Immunogenicity and protective efficacy in dogs of an MF59™-adjuvanted vaccine against recombinant canine/porcine coronavirus. Vaccine 29(11): 2018-2023, 2011

Efficacy of an inactivated feline panleucopenia virus vaccine against a canine parvovirus isolated from a domestic cat. Veterinary Record 157(10): 285-287, 2005

Efficacy of a combined live attenuated canine distemper and inactivated rabies vaccine in dogs. Indian Journal of Animal Sciences 65(5): 489-491, 1995

A novel canine favored CpG oligodeoxynucleotide capable of enhancing the efficacy of an inactivated aluminum-adjuvanted rabies vaccine of dog use. Vaccine 28(12): 2458-2464, 2010

Canine coronavirus vaccine from feline enteric coronavirus. Official Gazette of the United States Patent & Trademark Office Patents 1210(2): 1432, 1998

Protective efficacy and immunogenicity of an inactivated avian-origin H3N2 canine influenza vaccine in dogs challenged with the virulent virus. Veterinary Microbiology 143(2-4): 184-188, 2010

Genetic diversity of a canine coronavirus detected in pups with diarrhoea in Italy. Journal of Virological Methods 110(1): 9, 2003

Case report on mixed infection of canine parvovirus and canine coronavirus--electron microscopy and recovery of canine coronavirus. Nihon Juigaku Zasshi. Japanese Journal of Veterinary Science 45(2): 217-225, 1983

A case of mixed infection of canine parvovirus and canine coronavirus electron microscopy and recovery of canine coronavirus. Japanese Journal of Veterinary Science 45(2): 217-226, 1983